GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allakos Inc (STU:37Z) » Definitions » Cash Receipts from Loans

Allakos (STU:37Z) Cash Receipts from Loans


View and export this data going back to 2019. Start your Free Trial

What is Allakos Cash Receipts from Loans?

Cash Receipts from Loans only applicable to companies reporting Cash Flow from Operations in direct method.


Allakos Business Description

Industry
Traded in Other Exchanges
Address
825 Industrial Road, Suite 500, San Carlos, CA, USA, 94070
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.